In silico analysis of alternative splicing on drug-target gene interactions.
Ontology highlight
ABSTRACT: Identifying and evaluating the right target are the most important factors in early drug discovery phase. Most studies focus on one protein ignoring the multiple splice-variant or protein-isoforms, which might contribute to unexpected therapeutic activity or adverse side effects. Here, we present computational analysis of cancer drug-target interactions affected by alternative splicing. By integrating information from publicly available databases, we curated 883 FDA approved or investigational stage small molecule cancer drugs that target 1,434 different genes, with an average of 5.22 protein isoforms per gene. Of these, 618 genes have ≥5 annotated protein-isoforms. By analyzing the interactions with binding pocket information, we found that 76% of drugs either miss a potential target isof
SUBMITTER: Ji Y
PROVIDER: S-EPMC6954184 | biostudies-literature | 2020 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA